We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Summit Therapeutics (NASDAQ:SMMT) stands against the other stocks.
Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a shift toward tech innovation. The pace might slow after two years of significant returns, but investors have regained their confidence after the Stargate project was announced.
Small and mid-sized companies have started to pick up pace recently and are landing on investors’ radars as mega-cap stocks are now trading at nosebleed valuations. These companies have higher growth potential than their mega-cap rivals, and that explains the sudden surge of interest.
Smaller and mid-tier stocks did face challenges in prior years when corrections and interest rate hikes weighed on market sentiment. However, now that inflation seems more contained and Trump pushes for more rate cuts, things look even better for these mid-sized stocks.
Methodology
For this article, I screened the top-performing stocks year-to-date in the $5 billion to $20 billion market capitalization bracket. Stocks that I have covered recently will be excluded from this list.
I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds invest in? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).
A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample.
Summit Therapeutics (NASDAQ:SMMT)
Number of Hedge Fund Holders In Q3 2024: 21
Summit Therapeutics (NASDAQ:SMMT) is a biopharmaceutical company. It focuses on oncology and has therapies for non-small cell lung cancer.
The lead product here is ivonescimab, which is a bispecific antibody designed to block PD-1 and inhibit VEGF. The company has already reached multiple Phase III studies after the HARMONi banner in patients with EGFR-mutated NSCLC who have progressed after TKI therapy.
SMMT stock has risen significantly so far in 2025 due to it completing enrollment for its HARMONi Phase III trial and announcing that the FDA granted it fast-track designation for ivonescimab. This fueled a lot of optimism around the company.
Moreover, Summit Therapeutics has a cash reserve of around $410 million. That said, it is still pre-revenue, with a net loss of $56.3 million.
The average analyst price target is at $35.4, implying 49% upside.
SMMT stock is up 29.6% year-to-date.
Overall SMMT ranks 10th on our list of the stocks that are skyrocketing in 2025. While we acknowledge the potential of SMMT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SMMT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 10 Hottest Mid-Cap Stocks So Far in 2025 and 10 Hottest Smid-Cap Stocks So Far In 2025
Disclosure: None. This article was originally published at Insider Monkey.
